Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.

Trifarotene cream effective for face, trunk acne

28 May 2019
Patients with newly diagnosed acne were found to be at an increased risk of developing clinical depression compared to the general population.

Trifarotene is safe, well-tolerated and effective in treating both facial and truncal acne, according to two phase III trials.

Researchers conducted two double-blinded, randomized, vehicle-controlled trials: PERFECT 1 (n=1,208; mean age, 19.4±6.41 years; 52.1 percent female) and PERFECT 2 (n=1,212; mean age, 19.7±6.3 years; 57.3 percent female). In both studies, the primary endpoints were success rate on the face, as measured by the Investigator’s Global Assessment (IGA), and the absolute change from baseline in inflammatory and noninflammatory counts.

In PERFECT 1, the IGA success rate in the face in patients who received the trifarotene cream (n=612) was 29.4 percent. This was significantly higher than the corresponding rate in those randomly assigned to the vehicle cream (19.5 percent; p<0.001). A similar trend was observed for PERFECT 2 (42.2 percent vs 25.7 percent; p<0.001).

Trifarotene continued to trump the vehicle control in terms of primary endpoints. For instance, in PERFECT 1, there was a significantly greater absolute drop in inflammatory lesions in those who received the cream of interest (–19.0 vs –15.4; p<0.001). This remained true in PERFECT 2 (–24.2 vs –18.7; p<0.001).

Noninflammatory lesions likewise significantly decreased from baseline in both PERFECT 1 (–25.0 vs –17.9; p<0.001) and PERFECT 2 (–30.1 vs –21.6; p<0.001).

The significant benefits of trifarotene also extended to the trunk. The Physician’s Global Assessment success rates (PERFECT 1: 35.7 percent vs 25.0 percent; p<0.001; PERFECT 2: 42.6 percent vs 29.9 percent; p<0.001) and reductions in inflammatory (PERFECT 1: –21.4 vs –18.8; p<0.001; PERFECT 2: –25.5 vs –19.8) and noninflammatory (PERFECT 1: –21.9 vs –17.9; p<0.001; PERFECT 2: –25.9 vs –20.8; p<0.001) lesions were all significantly greater in those who received the trifarotene cream.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 3 days ago

The presence of pulmonary arterial hypertension (PAH) in individuals with systemic sclerosis is associated with an increased mortality risk, a study from Singapore showed.

23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Stephen Padilla, 6 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.
19 Jan 2020
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.